280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial

Rupert Bartsch, Anna S. Berghoff, Julia Furtner, Elisabeth Bergen, Sophie Roider‐Schur, Maximilian Marhold, Angelika M. Starzer, Heidrun Forstner, Beate Rottenmanner, Karin Dieckmann, Zsuzsanna Bagó-Horváth, Georg Widhalm, Aysegül Ilhan‐Mutlu, Christoph Minichsdorfer, Thorsten Fuereder, Christian F. Singer, A. Weltermann, Matthias Preusser